Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers

F. Coussy (1) , R. El Botty (2) , M. Lavigne (3) , C. Gu (3) , L. Fuhrmann (3) , A. Briaux (4) , L. de Koning (5) , A. Dahmani (6) , E. Montaudon (6) , L. Morisset (6) , L. Huguet (2) , L. Sourd (2) , P. Painsec (2) , S. Chateau-Joubert (7) , Thibaut Larcher (8, 9) , S. Vacher (4) , S. Melaabi (10) , A. Vincent Salomon (3) , E. Marangoni (2) , I. Bieche (2, 11, 12)

1 Unit of Pharmacogenomics, Department of Genetics,Laboratory of Preclinical Investigation, Department of Translational Research,Department of Medical Oncology
2 Laboratory of Preclinical Investigation, Department of Translational Research
3 Department of Biopathology
4 Unit of Pharmacogenomics, Department of Genetics
5 Translational Research Department, RPPA Platform
6 Laboratory of Preclinical Investigation, Department of Translational Research,
7 Biopôle Alfort
8 PAnTher - Physiopathologie Animale et bioThérapie du muscle et du système nerveux
9 APEX - Expertise en Anatomie Pathologique
10 Unit of Pharmacogenomics, Department of Genetics,
11 IC UM3 (UMR 8104 / U1016) - Institut Cochin
12 UPD5 - Université Paris Descartes - Paris 5

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers

Domaines: Sciences du Vivant [q-bio]

F. Coussy, R. El Botty, M. Lavigne, C. Gu, L. Fuhrmann, et al.. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers. Journal of Hematology and Oncology, 2020, 13 (1), ⟨10.1186/s13045-020-0846-y⟩. ⟨hal-02508763⟩